Aridis Pharma’s AR-501 an Orphan Drug in U.S. for CF lung infection

The FDA has granted Orphan Drug Designation (ODD) to Aridis Pharmaceuticals’ (NASDAQ:ARDS) AR-501, an inhaled formulation of gallium citrate for treatment of lung infection in patients with cystic fibrosis (CF).

Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.

https://seekingalpha.com/news/3474181-aridis-pharmas-arminus-501-orphan-drug-u-s-cf-lung-infection